TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

AUCTA

NeurologyRespiratory
Generics

AUCTA is a generic drug manufacturer focused on Neurology, Respiratory. Key products include MOTPOLY XR.

2018
Since
7
Drugs
-
Trials
57
Approved (2yr)

Key Drugs

VIGADRONE
vigabatrin
GABA-T 2 indications · 2018
ZELVYSIA
sapropterin dihydrochloride
Phenylalanine Hydroxylase 2 indications · 2025
MOTPOLY XR
lacosamide
Voltage-gated sodium channels 2 indications · 2023
PYQUVI
deflazacort
Rare Disease
Glucocorticoid Receptor 1 indications · 2025

Recent Activity

DEFERASIROX 2025-10-21
Labeling
DEFERASIROX 2025-10-21
Labeling
DEFERASIROX 2025-10-21
Labeling
DEFERASIROX 2025-10-21
Labeling
DEFERASIROX 2025-10-21
Labeling
DEFERASIROX 2025-10-21
Labeling
OXCARBAZEPINE 2025-09-17
Labeling
OXCARBAZEPINE 2025-09-16
Labeling
OXCARBAZEPINE 2025-09-08
Labeling
OXCARBAZEPINE 2025-09-08
Labeling
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Neurology 67%
2 drugs
Respiratory 33%
1 drugs

Pipeline Strength Pro

Loading...

Competitors Pro

GSK big-pharma
Respiratory, Neurology
Roche big-pharma
Neurology, Respiratory
GE HEALTHCARE specialty
Neurology, Respiratory
LEDERLE big-pharma
Neurology, Respiratory
ENDO OPERATIONS specialty
Respiratory, Neurology